DECOY THERAPEUTICS INC (DCOY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$2.76+4.94%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Control operating losses and improve net income: metric not reported.
Decoy Therapeutics is advancing its IMP3ACT platform with new leadership from MIT. The company raised capital through a private placement in June 2026. Despite losses, net income reached positive $16.06M in 2025-Q4, showing potential progress.
The company has persistent operating losses, with operating income as low as negative $9.03M in 2025-Q4. It faces Nasdaq listing compliance issues and negative cash flow from operations of negative $2.89M in 2026-Q1. Earnings are expected to remain negative through 2027.
The stock trades about 57% below our 12-month fair value of $26.86, reflecting high risk and expected negative earnings growth. The market prices in a challenging outlook with no revenue and worsening losses.
Breaks if: Private placement fails to close or raises significantly less capital than planned
Raise capital via private placement financing to fund clinical trial advancement of lead asset.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state indicates mixed signals, with management facing volatility and ongoing operating losses.
The market appears to price in a low level of fragility due to weak execution quality, suggesting that investors are cautious but not overly pessimistic. DCOY is seen as cheap compared to its peers, which may reflect the expectations gap.
Fundamentals are likely to remain under pressure as the company continues to manage negative cash flow and operating losses. Recent financial performance has been neutral, but the lack of clear improvement trends raises concerns.
The long-term thesis hinges on the performance of sector bellwethers and the company's ability to raise capital effectively. Monitoring compliance with Nasdaq requirements and addressing operational challenges will be critical.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q2. The company announced a private placement expected to provide approximately $3.5 million in gross proceeds to advance its lead asset into clinical trials. There is no prior quarter evidence of capital raising, so this is a new priority with initial delivery in funding secured.
“Decoy Therapeutics announced a private placement expected to provide approximately $3.5 million in gross proceeds at closing.”
Breaks if: Operating losses worsen beyond negative $9M or net income remains negative through FY27
Control operating losses and negative cash flow while progressing clinical development.
Stated as a priority in 8 of last 8 quarters. Operating income remained negative, with -$2.63M in 2026-Q2 and -$2.28M in 2026-Q1. Cash from operations was also negative, -$2.65M in 2026-Q2 and -$2.89M in 2026-Q1. The company continues to manage operating losses and negative cash flow, with no clear improvement trend, indicating limited progress on cost control.
“Operating income was -$2.63M and cash from operations was -$2.65M.”
“Operating income was -$2.28M and cash from operations was -$2.89M.”
“Operating income was -$9.03M and cash from operations was -$1.14M.”
“Operating income was -$0.90M and cash from operations was -$1.65M.”
“Operating income was -$0.97M and cash from operations was -$0.86M.”
“Operating income was -$1.72M and cash from operations was -$1.18M.”
“Operating income was -$1.49M and cash from operations was -$0.74M.”
“Operating income was -$1.01M and cash from operations was -$1.36M.”
Breaks if: Failure to regain compliance results in delisting or trading suspension
Maintain compliance with Nasdaq listing rules, specifically the minimum bid price requirement and related monitoring.
Newly stated in 2026-Q1. The company regained compliance with Nasdaq minimum bid price requirements as of March 31, 2026 and is under a one-year monitoring period. This addresses prior compliance issues but is only recently resolved with ongoing monitoring.
“Company received notification from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement.”
Over the next 1 to 3 years, DCOY's outlook is uncertain, influenced by sector performance and internal management execution. Not investment advice.